Results 1 to 10 of about 821 (87)

Intravitreal injection of ziv-aflibercept in the treatment of choroidal and retinal vascular diseases [PDF]

Journal of Current Ophthalmology, 2017
Purpose: To investigate the short-term outcomes after intravitreal injection of ziv-aflibercept in the treatment of choroidal and retinal vascular diseases.
Shiva Mehravaran, Hooshang Faghihi, Hassan Hashemi   +2 more
exaly   +4 more sources

One-year outcomes of ziv-aflibercept for macular edema in central retinal vein occlusion [PDF]

American Journal of Ophthalmology Case Reports, 2017
Purpose: To report the 12-month efficacy and safety outcomes of intravitreal ziv-aflibercept in macular edema secondary to central retinal vein occlusion (CRVO).
Errol W Chan, Chintan J Dedhia, Ahmad M Mansour   +2 more
exaly   +4 more sources

The sterility, stability and efficacy of repackaged ziv-aflibercept for intravitreal administration [PDF]

Scientific Reports, 2022
To evaluate the sterility, stability, and efficacy of repackaged ziv-aflibercept in 1-mL plastic tuberculin syringes for intravitreal injection after storage for up to 90 days at controlled (4 °C) and ambient (25.8 °C) temperature.
Jakkrit Juhong, Pear Ferreira Pongsachareonnont, Thanapong Somkijrungroj, Apivat Mavichak, Adisai Varadisai, Pajaree Chariyavilaskul, Tanittha Chatsuwan, Thitima Benjachat Suttichet, Kittisak Kulvichit   +8 more
doaj   +2 more sources

Effectiveness of the Use of Three-Dose Intravitreal Ziv-Aflibercept in the Management of Diabetic Macular Edema in a Real-Life Setting [PDF]

Clinical Ophthalmology, 2023
Fernando Munayco-Guillén,1,2 Miguel Angel Vazquez-Membrillo,1,2 Marlon Rafael Garcia-Roa,1,2 Jhony Alberto De La Cruz-Vargas,3 Herney Andrés García-Perdomo,4 Rafael Pichardo-Rodriguez3 1Department of Retina and Vitreous Surgery, Instituto Mexicano de ...
Munayco-Guillén F, Vazquez-Membrillo MA, Garcia-Roa MR, De La Cruz-Vargas JA, García-Perdomo HA, Pichardo-Rodriguez R   +5 more
doaj   +2 more sources

Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors [PDF]

Journal for ImmunoTherapy of Cancer, 2022
Background The combination of antiangiogenic agents with immune checkpoint inhibitors could potentially overcome immune suppression driven by tumor angiogenesis.
Howard Streicher, Elad Sharon, Mariano Severgnini, Michael Manos, Anita Giobbie-Hurder, F Stephen Hodi, Andrew S Brohl, Philippe L Bedard, Kevin Tyan, Scott Rodig, Osama E Rahma, Daniel J Renouf, Emma Hathaway, Rachel Cunningham   +13 more
doaj   +2 more sources

Switching to ziv-aflibercept in resistant diabetic macular edema non responsive to ranibizumab injection [PDF]

BMC Ophthalmology, 2022
Background Diabetic macular edema (DME) is a leading cause of visual loss in diabetic patients and is managed using multiple anti-vascular endothelial growth factor (VEGF) agents such as bevacizumab, ranibizumab and aflibercept.
Amin E. Nawar, Tamer Wasfy, Heba M. Shafik   +2 more
doaj   +2 more sources

12-month outcomes of ziv-aflibercept for neovascular age-related macular degeneration in eyes previously treated with aflibercept [PDF]

Indian Journal of Ophthalmology
Purpose: To investigate the 12-month outcomes of ziv-aflibercept for neovascular age-related macular degeneration (nAMD) in eyes previously treated with aflibercept.
Wajiha J Kheir, Mahdi Hassoun, Rola N Hamam, Ziad Fayez Bashshur   +3 more
doaj   +2 more sources

Intravitreal ziv-aflibercept in diabetic vitreous hemorrhage [PDF]

International Journal of Retina and Vitreous, 2020
Background To evaluate the safety and efficacy of intravitreal ziv-aflibercept (IVZ) in the management of vitreous hemorrhage (VH) in eyes with previously lasered proliferative diabetic retinopathy (PDR).
Ahmad M. Mansour, Mohammed Ashraf, Khalil M. El Jawhari, Michel Farah, Ahmed Souka, Chintan Sarvaiya, Sumit Randhir Singh, Alay Banker, Jay Chhablani   +8 more
doaj   +2 more sources

Phase I study of sapanisertib (CB‐228/TAK‐228/MLN0128) in combination with ziv‐aflibercept in patients with advanced solid tumors [PDF]

Cancer Medicine
Background Sapanisertib is a potent ATP‐competitive, dual inhibitor of mTORC1/2. Ziv‐aflibercept is a recombinant fusion protein comprising human VEGF receptor extracellular domains fused to human immunoglobulin G1.
Niamh Coleman, Bettzy Stephen, Siqing Fu, Daniel Karp, Vivek Subbiah, Jordi Rodon Ahnert, Sarina A. Piha‐Paul, John Wright, Senait N. Fessahaye, Fengying Ouyang, Bulent Yilmaz, Funda Meric‐Bernstam, Aung Naing   +12 more
doaj   +2 more sources

Pilot study of ziv-aflibercept in myopic choroidal neovascularisation patients [PDF]

BMC Ophthalmology, 2020
Background Myopic choroidal neovascularization (CNV) is the most common sight-threatening complication associated with high myopia. The present study evaluated the efficacy and safety of the intravitreal injection of ziv-aflibercept in patients with ...
Amin E. Nawar, Heba M. Shafik
doaj   +2 more sources